Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: A placebo-controlled trial-Reference-Cited by-同舟云学术

Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: A placebo-controlled trial

Published:2008-04 Issue:4 Volume:102 Page:479-487
ISSN:0954-6111
Container-title:Respiratory Medicine
language:en
Short-container-title:Respiratory Medicine

Author:

Tashkin Donald P.,Littner Michael,Andrews Charles P.,Tomlinson LaTanya,Rinehart Mike,Denis-Mize Kimberly

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference34 articles.

1. Global initiative for chronic obstructive lung disease (GOLD). Report of the GOLD workshop, global strategy for diagnosis, management and prevention of COPD, 2006 update. Available at: 〈http://www.goldcopd.com〉.

2. The role of long-acting bronchodilators in the management of stable COPD;Tashkin;Chest,2004

3. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial;Chest,1994

4. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD;Cazzola;Pulm Pharmacol Ther,2004

5. Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD;Richter;Respiration,2006

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Indian Guidelines on Nebulization Therapy;Indian Journal of Tuberculosis;2022

2. Pharmacological Management of Asthma and COPD;Reference Module in Biomedical Sciences;2021

3. Comparaciones entre asociaciones de broncodilatadores de larga duración para la enfermedad pulmonar obstructiva crónica;Open Respiratory Archives;2020-10

4. Bronchodilator efficacy of tiotropium/formoterol (18/12 µg once daily via a Discair inhaler), tiotropium alone (18 µg by Handihaler) or combined with formoterol (12 µg twice daily by Aerolizer) in adults with moderate-to-severe stable COPD;Current Medical Research and Opinion;2019-09-16

5. Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease;Expert Opinion on Pharmacotherapy;2019-02